scholarly journals Letter: renal tubular dysfunction during nucleotide analogue therapy in chronic hepatitis B

2012 ◽  
Vol 36 (10) ◽  
pp. 992-993 ◽  
Author(s):  
S. Manolakopoulos ◽  
A. Striki ◽  
G. V. Papatheodoridis
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Tubular Dysfunction ◽  
Renal Tubular Dysfunction ◽  
Nucleotide Analogue ◽  
Renal Tubular

scholarly journals Reversal of Proximal Renal Tubular Dysfunction after Nucleotide Analogue Withdrawal in Chronic Hepatitis B

2017 ◽  
Vol 2017 ◽  
pp. 1-8 ◽  
Author(s):  
Abhasnee Sobhonslidsuk ◽  
Pawin Numthavaj ◽  
Jirachaya Wanichanuwat ◽  
Areepan Sophonsritsuk ◽  
Supanna Petraksa ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Fractional Excretion ◽  
Tubular Dysfunction ◽  
Renal Tubular Dysfunction ◽  
Nucleotide Analogue ◽  
Proximal Renal Tubular Dysfunction ◽  
Renal Tubular ◽  
One Year

Aims. Proximal renal tubular dysfunction (PRTD) is an infrequent complication after nucleotide analogue therapy. We evaluated the outcomes of PRTD and nephrotoxicity after nucleotide analogue withdrawal in chronic hepatitis B (CHB). Methods. A longitudinal follow-up study was performed in patients with PRTD after nucleotide analogue discontinuation. Serum and urine were collected at baseline and every 3 months for one year. The fractional excretion of phosphate (PO4), uric acid (UA), and potassium and tubular maximal reabsorption rate of PO4 to glomerular filtration rate (TmPO4/GFR) were calculated. Renal losses were defined based on the criteria of substance losses. Subclinical PRTD and overt PRTD were diagnosed when 2 and ≥3 criteria were identified. Results. Eight subclinical and eight overt PRTD patients were enrolled. After nucleotide analogue withdrawal, there were overall improvements in GFR, serum PO4, and UA. Renal loss of PO4, UA, protein, and β2-microglobulin reduced over time. At one year, complete reversal of PRTD was seen in 13 patients (81.2%). Improvements in PRTD were seen in all but one patient. Conclusion. One year after nucleotide analogue withdrawal, PRTD was resolved in most patients. Changes in TmPO4/GFR, urinary protein, and β2-microglobulin indicate that urinary biomarkers may represent an early sign of PRTD recovery.

731 Nucleotide Analogue-Related Fanconi Syndrome and Severe Proximal Renal Tubular Dysfunction During the Treatment of Chronic Hepatitis B

2015 ◽  
Vol 148 (4) ◽  
pp. S-993
Author(s):  
Abhasnee Sobhonslidsuk ◽  
Jirachaya Wanichanuwat ◽  
Bunyong Phakdeekitcharoen ◽  
Areepan Sophonsritsuk ◽  
Supanna Petraksa ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Fanconi Syndrome ◽  
Tubular Dysfunction ◽  
Renal Tubular Dysfunction ◽  
Nucleotide Analogue ◽  
Proximal Renal Tubular Dysfunction ◽  
Renal Tubular

809 Reversal of Proximal Renal Tubular Dysfunction After Nucleotide Analogue Withdrawal in Chronic Hepatitis B

2016 ◽  
Vol 150 (4) ◽  
pp. S1048-S1049 ◽  
Author(s):  
Abhasnee Sobhonslidsuk ◽  
Jirachaya Wanichanuwat ◽  
Pawin Numthavaj ◽  
Areepan Sophonsritsuk ◽  
Supanna Petraksa ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Tubular Dysfunction ◽  
Renal Tubular Dysfunction ◽  
Nucleotide Analogue ◽  
Proximal Renal Tubular Dysfunction ◽  
Renal Tubular

scholarly journals Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B

2012 ◽  
Vol 35 (11) ◽  
pp. 1317-1325 ◽  
Author(s):  
N. Gara ◽  
X. Zhao ◽  
M. T. Collins ◽  
W. H. Chong ◽  
D. E. Kleiner ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Tubular Dysfunction ◽  
Renal Tubular Dysfunction ◽  
Renal Tubular

scholarly journals Tenofovir Alafenamide Rescues Renal Tubules in Patients with Chronic Hepatitis B

Life ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. 263
Author(s):  
Tomoya Sano ◽  
Takumi Kawaguchi ◽  
Tatsuya Ide ◽  
Keisuke Amano ◽  
Reiichiro Kuwahara ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Renal Dysfunction ◽  
Chronic Hepatitis B ◽  
Dramatic Improvement ◽  
Tubular Dysfunction ◽  
Renal Tubular Dysfunction ◽  
Renal Tubules ◽  
Long Term Treatment ◽  
Tenofovir Alafenamide

Nucles(t)ide analogs (NAs) are effective for chronic hepatitis B (CHB). NAs suppress hepatic decompensation and hepatocarcinogenesis, leading to a dramatic improvement of the natural course of patients with CHB. However, renal dysfunction is becoming an important issue for the management of CHB. Renal dysfunction develops in patients with the long-term treatment of NAs including adefovir dipivoxil and tenofovir disoproxil fumarate. Recently, several studies have reported that the newly approved tenofovir alafenamide (TAF) has a safe profile for the kidney due to greater plasma stability. In this mini-review, we discuss the effectiveness of switching to TAF for NAs-related renal tubular dysfunction in patients with CHB.

Sign in / Sign up

Export Citation Format

Share Document